Phase 2 Start~month

Phase 2 Start: A Phase 2, Multicenter, Double-Blind, Randomized, Controlled Trial of the Safety and Immunogenicity

Indication
Hematopoietic and Lymphatic System Neoplasm

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 2 Start: A Phase 2, Multicenter, Double-Blind, Randomized, Controlled Trial of the Safety and Immunogenicity — ARCT Phase 2 Start | BioSniper